First-Quarter 2023 Business Review

Marcy l’Étoile (France), April 27^th, 2023 – bioMérieux today releases its business review for the three months ended March 31^th, 2023. Consolidated sales totaled €906 million in the first quarter of 2023, up 8.2% from €837 million in the year‑earlier period.

Key highlights:

• Solid first-quarter sales performance with an organic growth of +7.5%
• This robust performance has been fueled by BIOFIRE^® non-respiratory panels growing a remarkable +32%, while respiratory panels remained positive at +3%
• Very good performance also in microbiology (+12%) and industrial applications (+9%)
• As a result, total non-respiratory sales organic growth reached +8.8%, in line with full-year guidance
• Strong momentum of product launches: key milestones have been achieved especially on VITEK^® REVEAL™, BIOFIRE^® SPOTFIRE^® and VIDAS^® KUBE™ fronts
• bioMérieux confirms its 2023 outlook for sales and operating profit, as published on March 8^th

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “bioMérieux had a good dynamic in this first-quarter, the company delivered a solid sales performance both in clinical and industrial applications. In line with its commitment to innovation for enhanced diagnostic, bioMérieux also had a strong momentum in terms of collaboration and key product launches.”